Abstracts tagged "pain"

Abstract Number: 1821 • 2019 ACR/ARP Annual Meeting
Tildrakizumab Efficacy for Psoriatic Arthritis: 24-week Analysis of Swollen and Tender Joint Counts and Pain
Ana-Maria Orbai ¹, Rocco Ballerini ², Richard C. Chou ³, Stephen Rozzo ², Alan Mendelsohn² and Luis R. Espinoza ⁴, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ³University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, ⁴Section of Rheumatology, LSU Health Sciences Center, New Orleans, LA, New Orleans, LA
Background/Purpose: Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved to treat moderate-to-severe plaque psoriasis. A randomized, double-blind, multidose, placebo (PBO)-controlled, phase 2b study (NCT02980692)…
Abstract Number: 1878 • 2019 ACR/ARP Annual Meeting
Quantifying the Placebo Effect After Intra-Articular Injections: Implications for Trials and Practice
Sebastian Rodriguez-Garcia¹, Raul Castellanos-Moreira ², Jacqueline Uson-Jaeger ³, ESPERANZA NAREDO ⁴ and Loreto Carmona ⁵, ¹Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Spain, ²Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, ³Hospital Universitario de Mostoles, Madrid, Spain, ⁴Rheumatology Department, Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz, Universidad Autónoma, MADRID, Spain, ⁵Instituto de Salud Musculoesquelética - Inmusc., Madrid, Spain
Background/Purpose: In recent years, diverse compounds for intra-articular (IA) administration were brought into the market with a subsequent significant and heterogeneous literature production. Understanding the efficacy…
Abstract Number: 1879 • 2019 ACR/ARP Annual Meeting
The Relation of Pain Sensitization and Conditioned Pain Modulation to Pain Patterns in Knee Osteoarthritis: The Multicenter Osteoarthritis Study
Lisa Carlesso¹, Laura Frey Law ², Na Wang ³, Michael Nevitt ⁴, Beth Lewis ⁵ and Tuhina Neogi ³, ¹McMaster University, Hamilton, ON, Canada, ²University of Iowa, Iowa City, IA, ³Boston University School of Medicine, Boston, MA, ⁴University of California at San Francisco, San Francisco, CA, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Intermittent pain progresses to constant pain in some, but not all, individuals with knee osteoarthritis (OA). Differing pain mechanisms may underlie these transitions. Later…
Abstract Number: 1881 • 2019 ACR/ARP Annual Meeting
Association of Pain Centralization with DMARD Response in Active RA
Andrew Heisler¹, Jing Song ², Dorothy Dunlop ¹, Alyssa Wohlfahrt ³, Marcy Bolster ⁴, Wendy Marder ⁵, Clifton Bingham ⁶, Daniel Clauw ⁷, Tuhina Neogi ⁸ and Yvonne Lee ⁹, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Northwestern University Feinberg School of Medicine, Worthington, OH, ³Brigham and Woman's Hospital, Boston, MA, ⁴Massachusetts General Hospital, Boston, MA, ⁵Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, ⁶Johns Hopkins University, Baltimore, MD, ⁷Division of Rheumatology, Department of Internal Medicine and Division of Anesthesia, Michigan Medicine, Ann Arbor, MI, ⁸Boston University School of Medicine, Boston, MA, ⁹Northwestern University Feinberg School of Medicine, Chicago
Background/Purpose: Despite the availability of potent disease modifying anti-rheumatic drugs (DMARDs), a significant percentage of rheumatoid arthritis (RA) patients do not achieve low disease activity…
Abstract Number: 1883 • 2019 ACR/ARP Annual Meeting
Elucidating Pain Mechanisms in Polyarticular Juvenile Idiopathic Arthritis Patients
Jaymin Upadhyay¹, Diana Sibai ¹, Robert Labadie ², Jordan Lemme ³, Christine Sieberg ², Kirsten Ecklund ⁴, David Borsook ⁴ and Robert Sundel ⁴, ¹Boston Children's Hospital, Harvard Medical School, Boston, MA, ²Boston Children’s Hospital, Harvard Medical School, Boston, MA, ³Boston Children's Hospital, Harvard Medical School, Boston, ⁴Boston Children’s Hospital, Harvard Medical School, Boston
Background/Purpose: Despite a broad range of available therapeutics, pain remains poorly treated in many juvenile idiopathic arthritis (JIA) patients1-2. For some patients, the level of pain…
Abstract Number: 2089 • 2019 ACR/ARP Annual Meeting
Restricting Activity to Evade Knee Symptoms Is Associated with Worse Physical Function and Radiographic Osteoarthritis
Louise Thoma¹, Jason Jakiela ², Hiral Master ¹, Dana Voinier ², Meredith Christiansen ² and Daniel White ¹, ¹University of Delaware, Newark, DE, ²University of Delaware, Newark
Background/Purpose: Activity restriction (i.e. limiting or avoiding normal activity) is a common strategy to reduce, and sometimes eliminate, knee symptoms. Knee symptoms, such as pain,…
Abstract Number: 2171 • 2019 ACR/ARP Annual Meeting
Functional Exercise for Adults with Chronic Nonspecific Low Back Pain
Emilia Moreira¹, Anamaria Jones ¹, Eider Lima ¹, Fabio Jennings ² and Jamil Natour ², ¹Federal University of Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ²Federal University of São Paulo, São Paulo, Brazil
Background/Purpose: To assess the effectiveness of a functional exercise program for pain, functional capacity, general health, kinesiophobia, medication consumption and patient satisfaction in adults with chronic…
Abstract Number: 2183 • 2019 ACR/ARP Annual Meeting
Relation of Intra-Articular Knee Mineralization on CT to Knee Pain in People with or at Risk of Knee Osteoarthritis
Tuhina Neogi¹, John Lynch ², Mohamed Jarraya ³, David Felson ⁴, Na Wang ¹, Michael Nevitt ², James Torner ⁵, Beth Lewis ⁶ and Ali Guermazi ¹, ¹Boston University School of Medicine, Boston, MA, ²University of California at San Francisco, San Francisco, CA, ³Mercy Catholic Medical Center, Darby, ⁴Boston University School of Medicine, Department of Rheumatology, Boston, ⁵University of Iowa at Iowa City, Iowa City, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Intra-articular (i.a.) calcium crystal deposition is common in knee osteoarthritis (OA), particularly in end-stage disease. It is possible that low-grade inflammation related to crystals…
Abstract Number: 2594 • 2018 ACR/ARHP Annual Meeting
Median Time to Pain Improvement in Patients with Psoriatic Arthritis Treated with Tofacitinib
Kurt de Vlam¹, Alexis Ogdie², Andrew G Bushmakin³, Joseph C Cappelleri³, Roy Fleischmann⁴, Peter C. Taylor⁵, Valderilio F Azevedo⁶, Lara Fallon⁷, Anna Maniccia⁸, John Woolcott⁹ and Philip J. Mease¹⁰, ¹UZ Leuven, Leuven, Belgium, ²University of Pennsylvania, Philadelphia, PA, ³Pfizer Inc, Groton, CT, ⁴University of Texas Southwestern Medical Center, Dallas, TX, ⁵University of Oxford, Oxford, United Kingdom, ⁶Universidade Federal do Paraná, Curitiba, Brazil, ⁷Pfizer Canada, Montreal, QC, Canada, ⁸Pfizer Inc, New York, NY, ⁹Pfizer Inc, Collegeville, PA, ¹⁰Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Pain is a core domain of psoriatic arthritis (PsA).1 Rapid, sustained pain reduction is a priority for patients (pts) and physicians when choosing treatment.…
Abstract Number: 2652 • 2018 ACR/ARHP Annual Meeting
Engaging the Cholinergic Anti-Inflammatory Pathway By Stimulating the Vagus Nerve Reduces Pain and Fatigue in Patients with SLE
Cynthia Aranow¹, Martin Lesser², Meggan Mackay¹, Erik Anderson³, Theodoros P. Zanos², Timir Datta-Chaudhuri², Chad Bouton², Kevin J. Tracey⁴ and Betty Diamond¹, ¹The Feinstein Institute for Medical Research, Manhasset, NY, ²Feinstein Institute for Medical Research, Manhasset, NY, ³Autoimmune and Musculoskeletal Disease, The Feinstein Institute for Medical Research, Manhasset, NY, ⁴Laboratory of Biomedical Science, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Musculoskeletal (MS) pain is a common symptom of patients with Systemic Lupus Erythematosus (SLE) affecting up to 95% of patients and contributing to…
Abstract Number: 2868 • 2018 ACR/ARHP Annual Meeting
Tender Joint Count May Not Reflect Inflammatory Activity in Established Rheumatoid Arthritis Patients; Results from a Longitudinal Study of Tocilizumab
Hilde B Hammer¹, Inger Marie Jensen Hansen², Pentti Järvinen³, Marjatta Leirisalo-Repo⁴, Michael Ziegelasch⁵, Birte Agular⁶ and Lene Terslev⁷, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Svendborg Hospital, Svendborg, Denmark, ³Rheumatology, Kiljava Medical Research, Kiljavan, Finland, ⁴Rheumatology, University of Helsinki, Helsinki, Finland, ⁵Rheumatology, University Hospital, Linköping, Linköping, Sweden, ⁶Roche, Copenhagen, Denmark, ⁷Rheumatology, Rigshospitalet Glostrup, Copenhagen, Denmark
Background/Purpose: Tender joints may be caused by non-inflammatory pathologies but are still included in composite scores like CDAI. The present objective was to explore the…
Abstract Number: 405 • 2018 ACR/ARHP Annual Meeting
Feasibility of Enabling Self-Management and Coping with Arthritic Pain Using Exercise (ESCAPE-Pain) Programme for Knee Osteoarthritis in Malaysia
Muhammad Kamil Che Hasan^1,2, Emma Stanmore² and Chris Todd², ¹Kulliyyah (Faculty) of Nursing, International Islamic University Malaysia (IIUM), Kuantan Pahang, Malaysia, ²Division of Nursing, Midwifery and Social Work, The University of Manchester, Manchester, United Kingdom
Background/Purpose: In Malaysia around one in ten older people are diagnosed with osteoarthritis (OA), with the knee being one of the most commonly affected areas.…
Abstract Number: 447 • 2018 ACR/ARHP Annual Meeting
Discriminating between Central & Peripheral Pain Sensitization Using a Slowly Repeated Evoked Pain Protocol
Manuel Romero¹, Stephen Bruehl², Gustavo A Reyes del Paso³ and Pablo De la Coba³, ¹University Hospital of Jaén, Jaén, Spain, ²Department of Anesthesiology, Vanderbilt University, Nashville, TN, ³Department of Psychology, University of Jaén, Jaén, Spain
Background/Purpose: In a prior study, the response of pain sensitization by fibromyalgia (FM) patients to a protocol of Slowly Repeated Evoked Pain (SREP)* was strongly…
Abstract Number: 450 • 2018 ACR/ARHP Annual Meeting
Injection Site Reaction Associated with Subcutaneous Biologic Agents and Methotrexate. Analysis from the Rhumadata® Clinical Database and Registry
Denis Choquette¹, Louis Bessette², Jacques Brown², Boulos Haraoui¹, Frédéric Massicotte¹, Jean-Pierre Pelletier¹, Jean-Pierre Raynauld¹, Marie-Anaïs Rémillard¹, Diane Sauvageau¹, Angèle Turcotte², Édith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ²Rheumatology, Centre de l'Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada
Background/Purpose: Injection Site Reaction (ISRs) are associated with the subcutaneous (SC) route of administration of all biologic agents, and 3% to 15% of patients reports…
Abstract Number: 933 • 2018 ACR/ARHP Annual Meeting
Inflammation in the Hippocampus Affects Insulin-like Growth Factor-1 Receptor Signaling and Contributes to Neurological Sequelae in Rheumatoid Arthritis
Karin Andersson¹, Caroline Wasén¹, Lina Juzokaite¹, Malin C Erlandsson^1,2, Anna Stokowska³, Lovisa Leifsdottir⁴, Marcela Pekna³, Milos Pekny³, Kjell Olmarker⁵, Rolf Heckemann^6,7,8, Marie Kalm⁹ and Maria I Bokarewa², ¹Department of rheumatology and inflammation research, University of Gothenburg, Gothenburg, Sweden, ²Rheumatology Clinic, Sahlgrenska University Hospital, Gothenburg, Sweden, ³Department of Clinical Neuroscience, University of Gothenburg, Gothenburg, Sweden, ⁴Rheumatology Clinics, Sahlgrenska University Hospital, Gothenburg, Sweden, ⁵Department of Medical Chemistry and Cell Biology, University of Gothenburg, Gothenburg, Sweden, ⁶Med Tech West at Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden, ⁷Department of Medical Radiation Science, University of Gothenburg, Gothenburg, Sweden, ⁸Faculty of Medicine, Imperial College London, London, United Kingdom, ⁹Department of Pharmacology, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: The central nervous system is not the primary target in rheumatoid arthritis (RA). However, neuropsychiatric symptoms including pain, depression and anxiety are common and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].